Antimalarial Drugs

Classification (BY LIFE-CYCLE STAGE — organizing principle)

Blood schizonticides(kill asexual erythrocytic stage=symptoms): chloroquine, quinine, artemisinins, mefloquine, atovaquone-proguanil. Tissue schizonticides(liver stage): primaquine(+HYPNOZOITES specifically), atovaquone-proguanil(also causal prophylaxis). Gametocytocides(sexual forms, transmission): primaquine, artemisinins. Chemoprophylaxis: chloroquine, doxycycline, mefloquine, atovaquone-proguanil.

Mechanism

Chloroquine: accumulates in acidic food vacuole via ION TRAPPING(weak base, protonated→trapped — SAME principle as Renal Pharmacology’s urinary alkalinization, here in a parasite organelle) → inhibits haem polymerase(normally converts toxic free haem from Hb digestion→inert haemozoin) → toxic haem accumulates→kills parasite. RAPID blood schizonticide. Resistance: PfCRT transporter pumps chloroquine OUT of food vacuole before it acts → widespread P. falciparum resistance(still effective vs most P. vivax).

Artemisinins(artesunate, artemether): endoperoxide bridge cleaved by IRON released during Hb digestion(same haem-liberating process, here ACTIVATES rather than being blocked) → reactive free radicals → broad protein alkylation/damage → FASTEST parasite clearance of any class. ACT(artemisinin combination therapy) = standard 1st-line uncomplicated falciparum — artemisinin’s SHORT t½(rapid kill, inadequate alone to fully clear/prevent recrudescence) + longer-acting partner(lumefantrine) clears residual burden + protects vs ARTEMISININ RESISTANCE emergence(SE Asia, actively monitored global concern) — same resistance-prevention logic as General Considerations/TB.

Primaquine: mechanism not fully elucidated — active metabolites interfere with parasite mitochondrial function+oxidative stress. UNIQUELY effective vs HYPNOZOITES(dormant P. vivax/ovale liver forms causing RELAPSE weeks-months later) → only drug achieving true “RADICAL CURE” preventing relapse in these 2 species → added to blood schizonticide therapy SPECIFICALLY for vivax/ovale, NOT falciparum(no hypnozoites).

Mefloquine: similar principle to chloroquine(food vacuole/haem detox disruption). Chemoprophylaxis + chloroquine-resistant strains. Limited by neuropsychiatric SE(below).

Atovaquone-proguanil: atovaquone = inhibits parasite mitochondrial electron transport(collapses membrane potential, selective vs human equivalent). Proguanil(prodrug→cycloguanil) = inhibits parasite DHFR(weak alone) BUT potentiates atovaquone SYNERGISTICALLY independent of own antifolate mechanism — DIFFERENT synergy type from cotrimoxazole’s sequential-blockade synergy(here = enhances atovaquone’s membrane-potential collapse).

Adverse Effects

Chloroquine: retinopathy(IRREVERSIBLE, dose/duration-related — monitor if used long-term for RA/lupus too) + pruritus(notably common/severe, West African descent — described population-specific pattern). QT prolongation(high dose).

Primaquine: HAEMOLYSIS in G6PD deficiency — among the MOST POTENT oxidant triggers of ANY drug(more severe than sulfonamide/dapsone) → MANDATORY G6PD screening before use(not just “consider,” genuinely required precaution).

Artemisinins: generally well tolerated; mild GI upset + rare DELAYED haemolysis(1-several weeks post-treatment, DIFFERENT mechanism from G6PD oxidant haemolysis — related to damaged/pitted erythrocytes surviving initial parasite kill).

Mefloquine: distinctive NEUROPSYCHIATRIC SE — vivid dreams, anxiety, rarely psychosis/seizures → avoided in psychiatric history, less favoured prophylaxis where alternatives(doxycycline, atovaquone-proguanil) suitable.

Quinine: CINCHONISM(named syndrome: tinnitus, headache, nausea, visual disturbance) — EXPECTED dose-related effect, not rare idiosyncratic reaction. + hypoglycaemia(stimulates INSULIN release — distinct mechanism from oral hypoglycaemics; complicates interpretation in severe malaria where hypoglycaemia also occurs from disease itself).

Clinical Relevance

Life-cycle-stage framework = what makes rational prescribing possible: a blood schizonticide clearing symptoms does NOT necessarily prevent RELAPSE in vivax/ovale(only primaquine’s hypnozoite activity does) — clinical cure(acute illness) vs RADICAL cure(prevents future relapse) distinction = exactly the reasoning determining whether primaquine gets added, and for WHICH Plasmodium species specifically.

Classification (by Stage of the Plasmodium Life Cycle Targeted)

Drug choice in malaria depends entirely on which parasite life-cycle stage a drug reaches, making this life-cycle stage the organizing principle for the whole topic, more so than any other Antimicrobials topic covered so far:

Blood schizonticides (kill the asexual erythrocytic stage responsible for clinical symptoms): chloroquine, quinine, artemisinin derivatives, mefloquine, atovaquone-proguanil
Tissue schizonticides (kill the liver/hepatic stage): primaquine (also active against hypnozoites, the dormant liver forms specific to P. vivax/P. ovale), atovaquone-proguanil (also has causal prophylactic/tissue activity)
Gametocytocides (kill the sexual forms responsible for transmission to the mosquito, without necessarily affecting clinical illness): primaquine, artemisinin derivatives
Chemoprophylactic agents: chloroquine, doxycycline, mefloquine, atovaquone-proguanil

Mechanism of Action

Chloroquine: accumulates in the parasite’s acidic food vacuole (a weak base, trapped by ion trapping once protonated in the acidic compartment — the identical ion-trapping principle already introduced under Renal Pharmacology’s urinary alkalinization discussion, here operating within a parasitic organelle rather than the kidney) and inhibits haem polymerase, the enzyme that normally converts toxic free haem (released as the parasite digests host haemoglobin for nutrition) into inert, insoluble haemozoin — without polymerization, toxic free haem accumulates and kills the parasite. Rapidly acting blood schizonticide, but widespread chloroquine resistance (via a parasite membrane transporter, PfCRT, that pumps chloroquine back out of the food vacuole before it can act) has substantially limited its use in most P. falciparum-endemic regions, though it remains effective against most P. vivax.

Artemisinin derivatives (artesunate, artemether): contain an endoperoxide bridge that is cleaved by iron released during parasitic haemoglobin digestion (the same haem-liberating process chloroquine’s mechanism depends on, here activating rather than being blocked by the drug) — this cleavage generates highly reactive free radicals that alkylate and damage parasite proteins broadly, a rapid, potent, relatively non-specific damage mechanism producing the fastest parasite clearance of any antimalarial class. Artemisinin-based combination therapy (ACT) — always combining an artemisinin derivative with a longer-acting partner drug (e.g. lumefantrine) — is now standard first-line therapy for uncomplicated P. falciparum malaria specifically because artemisinins themselves have a very short half-life (rapid initial parasite killing but inadequate on their own to fully clear infection or prevent recrudescence), with the partner drug clearing the residual parasite burden — and, per the same resistance-prevention logic already established across Antimicrobials — General Considerations/Antitubercular Drugs, combination also specifically protects against the emergence of artemisinin resistance, a genuinely serious, actively monitored global concern in parts of Southeast Asia.

Primaquine: mechanism not fully elucidated, but its active metabolites are thought to interfere with parasite mitochondrial function and generate oxidative stress — uniquely effective against hypnozoites, the dormant P. vivax/P. ovale liver-stage forms responsible for relapse (clinical recurrence weeks to months after apparently successful treatment of the initial blood-stage infection, since these species alone establish a persistent liver reservoir) — primaquine’s specific hypnozoite activity is the only way to achieve a true “radical cure” preventing relapse in these two species, which is why it’s added to blood schizonticide therapy specifically for vivax/ovale malaria and not for falciparum (which doesn’t form hypnozoites).

Mefloquine: mechanism similar in principle to chloroquine (accumulates in and disrupts the food vacuole/haem detoxification process), used mainly for chemoprophylaxis and chloroquine-resistant strains, but limited by a distinctive neuropsychiatric adverse-effect profile (below).

Atovaquone-proguanil: a combination exploiting two complementary mechanisms — atovaquone selectively inhibits parasite mitochondrial electron transport (collapsing the parasite’s mitochondrial membrane potential, a target with enough structural difference from the human mitochondrial equivalent to provide selectivity), while proguanil (itself a prodrug, activated to cycloguanil) inhibits parasite dihydrofolate reductase — proguanil’s own antifolate action is comparatively weak, but it substantially potentiates atovaquone’s effect synergistically even independent of its own antifolate mechanism, a specific, examined pharmacological synergy distinct from the sequential-blockade synergy already seen with cotrimoxazole (this synergy is thought to relate to proguanil enhancing atovaquone’s collapse of mitochondrial membrane potential, a genuinely different type of synergistic interaction).

Adverse Effects

Chloroquine: retinopathy (irreversible, dose/duration-related — a specific concern with long-term use, e.g. in rheumatoid arthritis/lupus where chloroquine/hydroxychloroquine is also used for its immunomodulatory property, requiring periodic ophthalmologic monitoring) and pruritus (notably common and often severe in patients of West African descent, a genuinely described population-specific adverse effect pattern). QT prolongation at high dose.

Primaquine: haemolysis in G6PD deficiency — primaquine is among the most potent oxidant-stress triggers of this reaction among all drugs causing it (a more severe risk than the sulfonamide/dapsone oxidant-haemolysis already covered elsewhere), making G6PD screening before primaquine use a specific, mandatory, frequently-examined precaution distinct from the “consider screening” framing appropriate for milder oxidant drugs.

Artemisinins: generally well tolerated; mild GI upset, and rare but recognized cases of delayed haemolysis occurring 1-several weeks after treatment (a distinct, separate mechanism from G6PD-related oxidant haemolysis, related to the drug’s own effect on damaged/pitted erythrocytes that survived the initial parasite-killing process).

Mefloquine: distinctive neuropsychiatric adverse effects — vivid dreams, anxiety, and, less commonly but seriously, psychosis and seizures — a specific, well-known reason mefloquine is avoided in patients with a psychiatric history and is a less favoured chemoprophylaxis choice where alternatives (doxycycline, atovaquone-proguanil) are suitable.

Quinine: cinchonism — a specific, named syndrome (tinnitus, headache, nausea, visual disturbance) at therapeutic-to-mildly-excessive doses, worth recognizing as an expected dose-related effect rather than a rare idiosyncratic reaction; also causes hypoglycaemia (stimulates insulin release, a specific mechanism worth distinguishing from oral hypoglycaemic drugs’ mechanisms, relevant since quinine is sometimes used in severe/complicated malaria where hypoglycaemia can also occur from the disease itself, complicating clinical interpretation).

Clinical Relevance

The life-cycle-stage framework is what makes rational antimalarial prescribing possible rather than arbitrary: a drug that clears blood-stage parasites and resolves symptoms (any blood schizonticide) does not necessarily prevent relapse in P. vivax/ovale (only primaquine’s hypnozoite activity does that), and understanding this distinction — clinical cure of the acute illness versus radical cure preventing future relapse — is precisely the reasoning that determines whether primaquine needs to be added to a treatment regimen, and for which Plasmodium species specifically.

Plasmodium life cycle (liver stage/hypnozoites → blood stage → gametocytes) with each drug class’s stage of action marked.
Chloroquine’s ion-trapping accumulation in the acidic food vacuole and haem polymerase blockade, alongside artemisinin’s iron-triggered endoperoxide activation in the same organelle.